The city of Houston, Texas, currently has 22 active clinical trials seeking participants for Depression research studies.
Telehealth Behavioral Activation for Teens
Recruiting
Behavioral activation is one such empirically supported intervention. Derived from cognitive-behavioral therapy, a well-established treatment for depression, behavioral activation uses psychoeducation and skill-building to increase an individual's engagement in valued and enjoyable activities (e.g., socializing with family and friends, exercising, participating in a hobby) in order to improve depressive symptoms. Research has shown that behavioral activation is an effective intervention for depr... Read More
Gender:
ALL
Ages:
Between 12 years and 18 years
Trial Updated:
07/18/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Depression, Suicide and Self-harm, Depression in Adolescence, Depression Mild, Depression Moderate, Depression Severe
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
Recruiting
Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Brain Health Consultants and TMS Center, Houston, Texas
Conditions: Treatment Resistant Depression
Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
Recruiting
The core objective of this study is to enhance the translational potential of this electroencephalogram (EEG) biomarker by using ketamine(KET)-induced gamma potentiation as a prognostic marker of 4-week treatment outcome. Previous research focused exclusively on KET-induced gamma band potentiation (GBP) in the context of a single infusion. Our study design captures the clinical variation associated with real-world treatment resistant depression (TRD) patients and allows us to analyze the relativ... Read More
Gender:
ALL
Ages:
Between 21 years and 45 years
Trial Updated:
07/17/2025
Locations: Wells Medicine, Houston, Texas +1 locations
Conditions: Healthy, Major Depressive Disorder, Treatment Resistant Depression
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality
Recruiting
The purpose of the study is to assess the safety and acceptability of up to two sequential administrations of 25 mg psilocybin with additional therapeutic support in decreasing suicidality in patients with Bipolar Disorder (BD II) depression.
Gender:
ALL
Ages:
Between 25 years and 70 years
Trial Updated:
07/15/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Bipolar II Disorder, Depression, Bipolar, Suicidality
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
Recruiting
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States. The treatment of the depressive episodes of bipolar disorder in the pediatric population has not been as widely studied as the treatment of depressive episodes in bipolar disorder in adults, therefore pharmacotherapeutic options are limited. Given the change in disease state and safety demonstrated in adults with depressive episodes associate... Read More
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
07/14/2025
Locations: McGovern Medical School /ID# 240779, Houston, Texas +2 locations
Conditions: Depression, Bipolar I Disorder
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
Recruiting
The goal of this clinical trial is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using Deep Brain Stimulation (DBS) as an adjunctive treatment of non-psychotic unipolar Major Depressive Disorder (MDD) in adults.
Gender:
ALL
Ages:
Between 22 years and 70 years
Trial Updated:
07/07/2025
Locations: CHI St. Luke's Health Baylor College of Medicine Med. Ctr, Houston, Texas +1 locations
Conditions: Treatment Resistant Depression
Improving Behavioral Health for Caregivers and Children After Pediatric Injury
Recruiting
Pediatric traumatic injury (PTI) is a public health priority, with more than 125,000 children experiencing injuries that require hospitalization each year. These children, and their caregivers, are affected in many ways that may affect quality of life, emotional and behavioral health, physical recovery, family roles and routines, and academic functioning; yet US trauma centers do not adequately address these outcomes and a scalable national model of care for these families is needed. This propos... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Children's Memorial Hermann Hospital, Houston, Texas
Conditions: Quality of Life, PTSD, Depression Not Otherwise Specified, Child Externalizing Behavior
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
07/03/2025
Locations: Clinical Site, Houston, Texas +1 locations
Conditions: Bipolar Depression
A Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar Depression
Recruiting
The purpose of this study is to o evaluate the antidepressant efficacy of the PEA in Bipolar Depression and the association between antidepressant response with endogenous cannabinoids and cytokine levels
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/25/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Bipolar Depression
Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression
Recruiting
We propose a clinical study of medial forebrain bundle DBS as a treatment in 20 patients with treatment refractory depression (TRD). Data from the University of Bonn indicates that surgical lesions of the medical forebrain bundle can produce therapeutic benefits in patients with depressive disorders, and suggest that DBS at the same site may also reduce symptomatology in these TRD patients (Schaepfer, 2013). Depression affects up to 10% of the US population and of those at least 10-15% do not be... Read More
Gender:
ALL
Ages:
Between 22 years and 70 years
Trial Updated:
06/17/2025
Locations: UT Center of Excellence on Mood Disorders, Houston, Texas
Conditions: Major Depressive Disorder, Treatment Resistant Depression
Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression
Recruiting
The overall objective of the investigators is to assess the therapeutic efficacy and tolerability of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow for treatment of treatment-resistant bipolar depression patient (TRBD).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/17/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Treatment-resistant Bipolar Depression
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
Recruiting
Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in baseline depressive symptom severity, based on multiple depression scale assessment tools at 12 months from randomization.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: The University Of Texas Medical School At Houston - UT Center Of Excellence On Mood Disorders, Houston, Texas +1 locations
Conditions: Treatment Resistant Depression